Literature DB >> 21828161

Novel techniques in the use of bivalirudin for cardiopulmonary bypass anticoagulation in a child with heparin-induced thrombocytopenia.

D Dragomer1, A Chalfant, R Biniwale, B Reemtsen, M Federman.   

Abstract

Heparin-induced thrombocytopenia (HIT) occurs in both the pediatric and adult populations after exposure to heparin. Bivalirudin has been used as an alternative to heparin for adults undergoing cardiac surgery and cardiopulmonary bypass, but has only been used minimally in children for this purpose. We report the successful use of bivalirudin for anticoagulation during cardiopulmonary bypass in a small child with HIT, using novel techniques not previously described.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828161     DOI: 10.1177/0267659111419037

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  4 in total

Review 1.  The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.

Authors:  Dheeraj Goswami; Matthew DiGiusto; Rajeev Wadia; Sean Barnes; Jamie Schwartz; Diana Steppan; Kristen Nelson-McMillan; Richard Ringel; Jochen Steppan
Journal:  J Cardiothorac Vasc Anesth       Date:  2020-01-21       Impact factor: 2.628

2.  Use of bivalirudin for anticoagulation during implantation of total artificial heart.

Authors:  Myke Federman; Douglas Dragomer; Stuart Grant; Brian Reemtsen; Reshma Biniwale
Journal:  J Extra Corpor Technol       Date:  2014-06

Review 3.  Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.

Authors:  Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Nov-Dec

4.  Perioperative care in an adolescent patient with heparin-induced thrombocytopenia for placement of a cardiac assist device and heart transplantation: case report and literature review.

Authors:  Mineto Kamata; Roby Sebastian; Patrick I McConnell; Daniel Gomez; Aymen Naguib; Joseph D Tobias
Journal:  Int Med Case Rep J       Date:  2017-02-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.